MedTrace Logo

Evaluation of S-600918 in Adults With Refractory Chronic Cough

NCT04110054 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 406

Last updated 2024-03-27

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared with placebo.

Conditions

  • Chronic Cough

Interventions

DRUG

S-600918

Tablets for oral administration

DRUG

Placebo to S-600918

Tablets for oral administration

Sponsors & Collaborators

  • Shionogi

    lead INDUSTRY

Principal Investigators

  • Shionogi Clinical Trials Administrator Clinical Support Help Line · Shionogi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-13
Primary Completion
2020-12-08
Completion
2020-12-28
FDA Drug
Yes

Countries

  • United States
  • Czechia
  • Japan
  • Poland
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04110054 on ClinicalTrials.gov